Long-term risk for subsequent leukemia after treatment for childhood cancer

A report from the Childhood Cancer Survivor Study

Kerri Nottage, Jennifer Lanctot, Zhenghong Li, Joseph P. Neglia, Smita Bhatia, Sue Hammond, Wendy Leisenring, Anna Meadows, Deokumar Srivastava, Leslie L. Robison, Gregory Armstrong

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Previous investigations of cancer survivors report that the cumulative incidence of subsequent leukemia plateaus between 10 and 15 years after primary therapy. Risk beyond 15 years has not been comprehensively assessed, primarily because of lack of long-term follow-up. Among 5-year survivors from the Childhood Cancer Survivor Study cohort, 13 pathologically confirmed cases of subsequent leukemia occurred ≥ 15 years after primary malignancy, with a mean latency of 21.6 years (range, 15-32 years). Seven were acute myeloid leukemia (2 acute promyelocytic leukemia with t(15;17), 2 with confirmed preceding myelodysplastic syndrome), 4 acute lymphoblastic leukemia (2 pre-B lineage, 1 T cell, 1 unknown), and 2 other. Two acute myeloid leukemia cases had the 7q- deletion. The standardized incidence ratio was 3.5 (95% confidence interval, 1.9-6.0). Median survival from diagnosis of subsequent leukemia was 2 years. This is the first description of a statistically significant increased risk of subsequent leukemia ≥ 15 years from primary diagnosis of childhood cancer.

Original languageEnglish (US)
Pages (from-to)6315-6318
Number of pages4
JournalBlood
Volume117
Issue number23
DOIs
StatePublished - Jun 9 2011
Externally publishedYes

Fingerprint

Leukemia
T-cells
Acute Myeloid Leukemia
Neoplasms
Acute Promyelocytic Leukemia
Myelodysplastic Syndromes
Incidence
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Cohort Studies
Confidence Intervals
T-Lymphocytes
Therapeutics

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Long-term risk for subsequent leukemia after treatment for childhood cancer : A report from the Childhood Cancer Survivor Study. / Nottage, Kerri; Lanctot, Jennifer; Li, Zhenghong; Neglia, Joseph P.; Bhatia, Smita; Hammond, Sue; Leisenring, Wendy; Meadows, Anna; Srivastava, Deokumar; Robison, Leslie L.; Armstrong, Gregory.

In: Blood, Vol. 117, No. 23, 09.06.2011, p. 6315-6318.

Research output: Contribution to journalArticle

Nottage, K, Lanctot, J, Li, Z, Neglia, JP, Bhatia, S, Hammond, S, Leisenring, W, Meadows, A, Srivastava, D, Robison, LL & Armstrong, G 2011, 'Long-term risk for subsequent leukemia after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study', Blood, vol. 117, no. 23, pp. 6315-6318. https://doi.org/10.1182/blood-2011-02-335158
Nottage, Kerri ; Lanctot, Jennifer ; Li, Zhenghong ; Neglia, Joseph P. ; Bhatia, Smita ; Hammond, Sue ; Leisenring, Wendy ; Meadows, Anna ; Srivastava, Deokumar ; Robison, Leslie L. ; Armstrong, Gregory. / Long-term risk for subsequent leukemia after treatment for childhood cancer : A report from the Childhood Cancer Survivor Study. In: Blood. 2011 ; Vol. 117, No. 23. pp. 6315-6318.
@article{1f49759ec9a94f80a3107c9e679d33f1,
title = "Long-term risk for subsequent leukemia after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study",
abstract = "Previous investigations of cancer survivors report that the cumulative incidence of subsequent leukemia plateaus between 10 and 15 years after primary therapy. Risk beyond 15 years has not been comprehensively assessed, primarily because of lack of long-term follow-up. Among 5-year survivors from the Childhood Cancer Survivor Study cohort, 13 pathologically confirmed cases of subsequent leukemia occurred ≥ 15 years after primary malignancy, with a mean latency of 21.6 years (range, 15-32 years). Seven were acute myeloid leukemia (2 acute promyelocytic leukemia with t(15;17), 2 with confirmed preceding myelodysplastic syndrome), 4 acute lymphoblastic leukemia (2 pre-B lineage, 1 T cell, 1 unknown), and 2 other. Two acute myeloid leukemia cases had the 7q- deletion. The standardized incidence ratio was 3.5 (95{\%} confidence interval, 1.9-6.0). Median survival from diagnosis of subsequent leukemia was 2 years. This is the first description of a statistically significant increased risk of subsequent leukemia ≥ 15 years from primary diagnosis of childhood cancer.",
author = "Kerri Nottage and Jennifer Lanctot and Zhenghong Li and Neglia, {Joseph P.} and Smita Bhatia and Sue Hammond and Wendy Leisenring and Anna Meadows and Deokumar Srivastava and Robison, {Leslie L.} and Gregory Armstrong",
year = "2011",
month = "6",
day = "9",
doi = "10.1182/blood-2011-02-335158",
language = "English (US)",
volume = "117",
pages = "6315--6318",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "23",

}

TY - JOUR

T1 - Long-term risk for subsequent leukemia after treatment for childhood cancer

T2 - A report from the Childhood Cancer Survivor Study

AU - Nottage, Kerri

AU - Lanctot, Jennifer

AU - Li, Zhenghong

AU - Neglia, Joseph P.

AU - Bhatia, Smita

AU - Hammond, Sue

AU - Leisenring, Wendy

AU - Meadows, Anna

AU - Srivastava, Deokumar

AU - Robison, Leslie L.

AU - Armstrong, Gregory

PY - 2011/6/9

Y1 - 2011/6/9

N2 - Previous investigations of cancer survivors report that the cumulative incidence of subsequent leukemia plateaus between 10 and 15 years after primary therapy. Risk beyond 15 years has not been comprehensively assessed, primarily because of lack of long-term follow-up. Among 5-year survivors from the Childhood Cancer Survivor Study cohort, 13 pathologically confirmed cases of subsequent leukemia occurred ≥ 15 years after primary malignancy, with a mean latency of 21.6 years (range, 15-32 years). Seven were acute myeloid leukemia (2 acute promyelocytic leukemia with t(15;17), 2 with confirmed preceding myelodysplastic syndrome), 4 acute lymphoblastic leukemia (2 pre-B lineage, 1 T cell, 1 unknown), and 2 other. Two acute myeloid leukemia cases had the 7q- deletion. The standardized incidence ratio was 3.5 (95% confidence interval, 1.9-6.0). Median survival from diagnosis of subsequent leukemia was 2 years. This is the first description of a statistically significant increased risk of subsequent leukemia ≥ 15 years from primary diagnosis of childhood cancer.

AB - Previous investigations of cancer survivors report that the cumulative incidence of subsequent leukemia plateaus between 10 and 15 years after primary therapy. Risk beyond 15 years has not been comprehensively assessed, primarily because of lack of long-term follow-up. Among 5-year survivors from the Childhood Cancer Survivor Study cohort, 13 pathologically confirmed cases of subsequent leukemia occurred ≥ 15 years after primary malignancy, with a mean latency of 21.6 years (range, 15-32 years). Seven were acute myeloid leukemia (2 acute promyelocytic leukemia with t(15;17), 2 with confirmed preceding myelodysplastic syndrome), 4 acute lymphoblastic leukemia (2 pre-B lineage, 1 T cell, 1 unknown), and 2 other. Two acute myeloid leukemia cases had the 7q- deletion. The standardized incidence ratio was 3.5 (95% confidence interval, 1.9-6.0). Median survival from diagnosis of subsequent leukemia was 2 years. This is the first description of a statistically significant increased risk of subsequent leukemia ≥ 15 years from primary diagnosis of childhood cancer.

UR - http://www.scopus.com/inward/record.url?scp=79959402991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959402991&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-02-335158

DO - 10.1182/blood-2011-02-335158

M3 - Article

VL - 117

SP - 6315

EP - 6318

JO - Blood

JF - Blood

SN - 0006-4971

IS - 23

ER -